FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure
This article was originally published in The Gray Sheet
Executive Summary
The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said
You may also be interested in...
FDA Chief Counsel Bradshaw Brings DoJ Experience, Utah Political Ties
Sheldon Bradshaw brings high-level government experience and strong political connections to the top legal position at FDA
FDA Chief Counsel Bradshaw Brings DoJ Experience, Utah Political Ties
Sheldon Bradshaw brings high-level government experience and strong political connections to the top legal position at FDA
Troy joins Sidley Austin Brown & Wood
Former FDA Chief Counsel Dan Troy accepts position in firm's Life Sciences Practice & Appellate Litigation Group. He will focus on administrative and constitutional law and litigation, especially for the pharmaceutical, medical device and biotechnology industries, according to a Jan. 6 release. Colleen Klasmeier, who served as special assistant to the chief counsel under Troy, also is joining Sidley's Life Sciences Practice. Gerald Masoudi, formerly with Kirkland & Ellis, replaced Troy at FDA in November (1"The Gray Sheet" Nov. 22, 2004, p. 4)...